Slide 1: Investor Presentation Q2'26
Investor Presentation Q2’26 TM
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: Management Commentary on Q2 FY26 results
Management Commentary on Q2 FY26 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer We delivered strong growth for the fourth consecutive quarter, driven by In Q2FY26, our focus was on executing our strategic priorities: continued momentum in deal wins and
Slide 4: Q2 FY26: Financial Highlights
Q2 FY26: Financial Highlights INR 8,042 Mn 17.1% 12.4% Significant Revenue from YoY revenue growth in YoY revenue growth in Operations INR terms USD terms growth at scale INR 1,461 Mn INR 1,021 Mn Adj EBITDA(1) PAT Strong margin profile 15.3% YoY 11.3% YoY © 2025 Indegene. All rights reserved. (1) E
Slide 5: H1 FY26: Financial Highlights
H1 FY26: Financial Highlights INR 15,650 Mn 14.8% 11.0% Significant Revenue from YoY revenue growth in YoY revenue growth in Operations INR terms USD terms growth at scale INR 3,004 Mn INR 2,185 Mn Adj EBITDA(1) PAT Strong margin profile 15.7% YoY 21.8% YoY © 2025 Indegene. All rights reserved. (1)
Slide 6: Q2 FY26: Business Highlights
Q2 FY26: Business Highlights 76 (70) 40 (40) 63% (63%) Significant Active Client Relationships Clients with $1 Million+ Revenue from Top 20 Global Revenue Biopharma(1) Companies growth at scale 5,245/4,523 26.3% 16.2% (5,087/4,394) (24.8%) (16.8%) Global Total Employees / Delivery Headcount with Vol
Slide 7: Q2 FY26: Stable business mix
Q2 FY26: Stable business mix Revenue from Service Revenue by Customer Revenue by Customer offering ($Mn) Industry (%) Geography (%) 82.0 88.9 92.2 1.5% 3.5% 3.4% 3.5% 3.6% 3.1% 11.6% 10.0% 7.9% 2.7% 27.0% 69.6% 56.2% 58.5% 60.6% 0.7% 28.8% 28.0% 27.9% 92.0% Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY26 Q2 FY26 En
Slide 8: Indegene - Positioned for success in the GenAI era
Indegene - Positioned for success in the GenAI era Rich domain expertise & understanding of pharma operations and smart & timely investments in technology have positioned Indegene well • Unique business model with the widest • Integrated with well-established third-party technology breadth of capabi
Slide 9: Changing US Policies impacts life science industry minimally, not disruptive
Changing US Policies impacts life science industry minimally, not disruptive Most Favored Nation pricing Tariffs on Pharmaceutical D2C Marketing Restrictions • US Government has been pushing pharma Imports • US government wants to restrict “deceptive” or industry to bring price parity between drugs
Slide 10: Q2 FY26: Segment Performance Update
Q2 FY26: Segment Performance Update Amount in INR Mn Segment performance QoQ Segment performance YTD 9,328 4,453 4,874 7,612 4,374 1,621 1,395 2,132 2,242 758 638 3,866 534 265 288 553 ECS EMS BRAND OTHERS ECS EMS BRAND OTHERS ACTIVATION ACTIVATION Q1 FY26 Q2 FY26 Q2 FY25 Q2 FY26 • Core segments (EC
Slide 11: Growth Approach 1: Deeper Engagement with Large Pharma Customers
Growth Approach 1: Deeper Engagement with Large Pharma Customers Amount in INR Mn Revenue from Top 5 customers Revenue from Top 20 customers 76% 46% 84% 78% 49% 40% 38% 84% 55% 86% 21,657 22,082 23,224 11,345 11,984 11,347 11,664 19,321 9,176 14,320 FY22 FY23 FY24 FY25 Q2 FY26 TTM FY22 FY23 FY24 FY2
Slide 12: Growth Approach 2: Broader targeting leading to a wider, taller pyramid
Growth Approach 2: Broader targeting leading to a wider, taller pyramid 76 Active clients(1) 40 $1Mn+ Clients 30 Active clients(1) added since FY22 Active client base(1) Successful track record of growing accounts 41 40 35 2 2 34 3 8 9 28 4 4 6 3 2 73 76 62 63 31 29 23 26 26 46 FY22 FY23 FY24 FY25 Q
Slide 13: Strategic Initiatives - FY26
Strategic Initiatives - FY26 Tectonic Sales and GTM Investments in Building M&A • Indegene’s strategic Reorg Business organizational • Identified priority areas initiative on large for M&A including transformative change • Strategic review of Capability processes Commercial capability account covera
Slide 14: Enhancing credibility with industry recognition
Enhancing credibility with industry recognition Analyst Recognition Awards © 2025 Indegene. All rights reserved. 14
Slide 15: Indegene Digital Summit 2025 | Commercial
Indegene Digital Summit 2025 | Commercial Philadelphia 14th Sep 12 Venue Date Number of sessions Jared Juanjo Brian Marion 15 C. Dr. Andrew Josleyn Francesch Cantwell Dumas von SVP, Global CIO VP, Digital Global Head of Eschenbach Head of Digital Merck Animal Strategy and Omnichannel Former Commissi
Slide 16: Indegene Digital Summit 2025 | Medical and Clinical
Indegene Digital Summit 2025 | Medical and Clinical Virtual 15th Oct 17 Venue Date Number of sessions Aida Conor Craig Robert V. Dr. Deepshikha Habtezion Grennan Lipset Brown Thakur Former Pfizer Chief AI Architect Co-Chair, Senior Vice Founder Autism Doctor CMO, Adjunct NYU Stern School Decentraliz
Slide 17: Financial Highlights
Financial Highlights © 2025 Indegene. All rights reserved. 17
Slide 18: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet Adj EBITDA and Adj EBITDA PAT and PAT Margin Cash and Cash Equivalent(1) Margin (2) INR Mn and % INR Mn INR Mn and % 15.3% 20.3% 18.2% 12.7% 18.4% 13.4% 1,164 17,280 18,200 1,543 1,461 1,021 14,666 1,267 917 Q2 FY25 Q1 FY26 Q2 FY26 Q2 FY25 Q1 FY26 Q2 F
Slide 19: Q2 FY26 Consolidated Financials
Q2 FY26 Consolidated Financials Amount in INR Mn Particulars Q2 FY26 Q1 FY26 Q2 FY25 QoQ % YoY% Revenue from Operations 8,042 7,608 6,868 5.7% 17.1% Employee Benefit Expenses 5,158 4,815 4,420 7.1% 16.7% Other Expenses 1,436 1,233 1,187 16.5% 21.0% Other Income 12 -17 6 -174.5% 107.7% Adj EBITDA(1)
Slide 20: Annexure
Annexure © 2025 Indegene. All rights reserved. 20
Slide 21: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology The world’s top 20 biopharma companies trust us 26 Years > 26% 600+ Healthcare Employees With Dedicated Team For Innovative Domain Expertise Healthcare Background Technologies • Practitioner knowledge Healthcare Technology • Digital-first a
Slide 22: We Provide Capabilities and Expertise Across the Commercialization Value Chain
We Provide Capabilities and Expertise Across the Commercialization Value Chain Strategy Sales and Marketing Medical & Regulatory Affairs, R&D / Clinical Build and connect brand strategy to Pharmacovigilance Transform clinical trials by unlocking omnichannel HCP and patient engagement Communicate sci
Slide 23: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Life Sciences Operations Spend Across Expanding our TAM Inflection Point Verticals ($B) We Offer Solutions Across Life Sciences ~9-14% Patent Cl
Slide 24: Thank You!
Thank You! www.indegene.com
Slide 25: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2026 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Sep 30, Jun 30, Sep 30, No. YoY QoQ 2025 2025 2024 1. Active clients (1) (No.) 76 70 68 2. Revenue from operations 8,042 7,
Slide 26: Fact Sheet
Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2026 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Sep 30, Jun 30, Sep 30, YoY QoQ 2025 2025 2024 Biopharma 92.0 94.1 94.1 14.5 3.3 Medical Devices 3.5 2.5 2.4 72.0 45.8 Emerging Biotech 3.1 2.3 2.6